Page last updated: 2024-11-12
spiro-mamakone a
Description
spiro-mamakone A: spirobisnaphthalene derivative with a spiro-nonadiene skeleton from cultured nonsporulating fungal endophyte derived from the New Zealand native tree Knightia excelsa (rewarewa); structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Knightia | genus | [no description available] | Proteaceae | A plant family of the order Proteales, subclass Rosidae class Magnoliopsida. Cluster roots, bottlebrush-like clusters of rootlets which form in response to poor soil, are common in this family.[MeSH] |
| Knightia excelsa | species | [no description available] | Proteaceae | A plant family of the order Proteales, subclass Rosidae class Magnoliopsida. Cluster roots, bottlebrush-like clusters of rootlets which form in response to poor soil, are common in this family.[MeSH] |
Cross-References
Synonyms (4)
| Synonym |
|---|
| CHEMBL2414478 |
| spiro-mamakone a |
| 889098-19-5 |
| DTXSID601047548 |
Research
Studies (5)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 12.63
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 12.63 (24.57) | | Research Supply Index | 1.79 (2.92) | | Research Growth Index | 4.42 (4.65) | | Search Engine Demand Index | 0.00 (26.88) | | Search Engine Supply Index | 0.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |